Selank — Research Profile
Selank is a synthetic heptapeptide derived from a fragment of the immunoglobulin tuftsin. Research has examined its action on GABAergic signaling, BDNF expression, and anxiolytic-related behavioral...
Overview
Selank is a synthetic heptapeptide derived from a fragment of the immunoglobulin tuftsin. Research has examined its action on GABAergic signaling, BDNF expression, and anxiolytic-related behavioral models in rodents.
History
Selank emerged from Russian peptide research in the 1990s investigating modified tuftsin fragments. Its profile contrasts with classical benzodiazepine-pathway anxiolytics in receptor-binding studies.
Selank Structure
- CAS #: 129954-34-3
- Molecular Formula: C₃₃H₅₇N₁₁O₉
- Molecular Weight: 751.88 g/mol
- PubChem ID: 11765637
Research Findings
Selank research has explored GABAergic and serotonergic modulation, BDNF expression, and rodent behavioral models including elevated plus-maze and open-field paradigms.
Key Areas of Research
- GABAergic: receptor expression modulation
- Neurotrophic: BDNF pathway studies
- Behavioral: rodent anxiety models
Selank represents an alternative peptide pathway to classical anxiolytics in neuropeptide research.
References
- [1]Kozlovskaya M. M. et al. Selank — pharmacology and clinical potential of a new anxiolytic peptide. (2003).
- [2]Volkova A. et al. Selank and BDNF expression in rodent brain. (2016).
All references link to the corresponding PubMed record. Citations maintained for transparency — Viora articles are sourced from the published research literature.